Monday, 16 November 2026 X LinkedIn Bluesky RSS Send us news
LungDaily The Pulse of Respiratory Health
World COPD Day is on Wednesday 18 November · #WorldCOPDDay Our coverage →
Approvals & Trials

Zipalertinib plus chemotherapy heads toward FDA review in EGFR exon 20 insertion-mutated lung cancer

Oncodaily reports that the combination is moving toward review by the US Food and Drug Administration after a six-month progression-free survival benefit.

Zipalertinib combined with chemotherapy is moving toward review by the US Food and Drug Administration (FDA) for lung cancer with EGFR exon 20 insertion mutations, according to a news item published by Oncodaily on 13 November 2026.

The item's headline links the regulatory step to a six-month benefit in progression-free survival (PFS) in this patient population.

The text available for this report consists only of that headline. It does not give trial design, patient numbers, comparator arm, safety findings, the submitting company or a timeline for the FDA's decision. LungDaily has therefore not included those details. Further information would need to come from the full Oncodaily report or from primary announcements.

Original source

Zipalertinib Plus Chemotherapy Moves Toward FDA Review After Six-Month PFS Benefit in EGFR Exon 20 Insertion-Mutated Lung Cancer https://news.google.com/rss/articles/CBMiaEFVX3lxTE80Umh3WGEyMW9ZaURrekE4VUU2Y2plNEVGN19KbHNMc3dldUtJc3kyZTkzdnBDejBmMXMwMlVBTnBZOUoxQ0VKOE9BMGR0R0ZfMXVmMjRubHBpbFZIUkMzd2FNRlhyQnJR?oc=5

#lung-cancer#therapeutics

Related stories

More in Approvals & Trials

See all

LungDaily reports on public posts, papers and news from the lung health community. This article is based on the source linked above and was produced with AI-assisted tools under our editorial standards; facts and quotes are checked against the original before publication. Featured here, or spotted an error? Request a correction or removal.